Maxillary Mucormycosis Osteomyelitis in Post COVID-19 Patients: A Series of Fourteen Cases
Wael Mohamed Said Ahmed, Amira M. Elsherbini, Nehal M. Elsherbiny, Mohamed El‐Sherbiny, Nevine I. Ramzy, Ahmed F. Arafa
Abstract
During the current pandemic of COVID-19, numerous manifestations and complications have developed. Patients with COVID-19 are at high risk of fungal infections, such as mucormycosis, that may result directly from COVID-19 infection and/or as a side effect of the drugs used in COVID-19 treatment protocol, such as dexamethasone, hydroxychloroquine, and antibiotics. In this report, we described a series of 14 cases with maxillary mucormycosis osteomyelitis in immediate post-COVID-19 patients.
Topics & Concepts
MucormycosisCoronavirus disease 2019 (COVID-19)MedicineOsteomyelitisHydroxychloroquinePandemicDexamethasoneDermatologySurgeryInternal medicineDiseaseInfectious disease (medical specialty)Antifungal resistance and susceptibilitySarcoidosis and Beryllium Toxicity ResearchInfectious Diseases and Tuberculosis